Ebola Virus Complete Fact Sheet

Ebola virusEbola virus disease (EVD), better known in past as viral hemorrhagic fever, could be a severe, typically fatal human disease. The Ebola virus causes an acute, serious illness, which is commonly fatal if untreated. Ebola virus disease (EVD) first appeared in 1976 in a pair of coinciding outbreaks, one in Nzara, Sudan, and the other in Yambuku, Democratic Republic of Congo. The latter occurred in an exceedingly village close to the Ebola river, which it takes its name.

Pharmacology Refresh Cards: Noradrenaline - Norepinephrine

Noradrenaline  -  norepinephrine
Drug name
Sympathomimetic   (Vasopressor)
Group
Stimulates alpha-receptors in arterial and venous beds and beta1 receptors of heart, resulting in peripheral vasoconstriction and stimulation of heart rate and contractility. Coronary vasodilation occurs secondary to enhanced myocardial contractility.
Mechanism of action
duration
Interval
dose
Uses

Cont. infusion
0.01–0.4 µg/kg/min IV infusion via a central vein         
Septic shock ,with low SVR
Severe hypertension may occur if noradrenaline is given to patients taking tricyclic antidepressants since tricyclics block the uptake of noradrenaline into nerve endings.
Drug interaction
Bradycardia
Hypertension
Arrhythmias
Myocardial ischaemia
peripheral ischaemia
Side effects

Hypovolaemic shock
Acute myocardial ischaemia or MI
Contraindication & precaution
Pregnancy: Category D
Special populations

Norepinephrine may lose potency in normal saline solution
Administer in D5W or 5% dextrose in saline
If extravasation occurs, infiltration with phentolamine
Administration notes
4mg/4ml amp
Availability in pharmacy

Other notes

Calcium Carbonate versus Calcium Acetate as Phosphate binder

Phosphate binder
Ph D: Neven Mohamed
For many years, calcium-containing phosphate binders (calcium acetate and calcium carbonate) were considered the best choice in the treatment of hyperphosphatemia, due to they are effective, possessed only moderate side-effects and suppressed parathormone levels with the intention of counteracting progression of secondary hyperparathyroidism. In two head-to-head observational studies (CARE, ARNOS), calcium-containing binders showed signals of clinical superiority versus the comparator sevelamer-HCl.[1.2] 

Nevertheless, calcium may be absorbed significantly, which may result in a positive calcium balance and actively contribute progressive cardiovascular and soft-tissue calcification in patients at risk.[3]

15 Facts about HARVONI the recent Hepatitis C from Gilead

HARVONI is a combination of ledipasvir (90mg), a (HCV) NS5A inhibitor, and sofosbuvir (400mg), an HCV nucleotide analog NS5B polymerase inhibitor. HARVONI was approved by FDA on 10 October 2014, as first Hepatitis C drug combination, that used alone without need to ribavirin or peginterferon alfa, as in case of SOVALDI.

Here are 15 facts about the new drug, that pharmacist needs to know to help him in dealing with the Hepatitis C newest treatment.

Facts about SOVALDI Therapy

SOVALDI is a nucleotide analog polymerase inhibitor, that use in patients with chronic hepatitis C, in combination with ribavirin or interferon plus ribavirin, and the cure rate in clinical trials reached 95%.

SOVALDI is a nucleotide analog polymerase inhibitor, that use in patients with chronic hepatitis C, in combination with ribavirin or interferon plus ribavirin, and the cure rate in clinical trials reached 95%
Here is some facts about SOVALDI that pharmacist must know:
1-Active constituent of SOVALDI is sofosbuvir 400 mg.
2-SOVALDI is effective against the four genotypes of HIV infection, including patients with HCC that in waiting list for liver transplantation, and those carrying HIV-1/HCV co-infection.
3-SOVALDI not recommended using alone for Chronic Hepatitis C patients.
4-The dose of SOVALDI is 400 mg once daily, to be taken regardless of food.
5-Genotype-1 HCV treated for 12 weeks with SOVALDI +Peginterferon alfa +ribavirin, and for 24 weeks if used without peginterferon alfa.